Form D · Biotechnology
Vaxin Inc.
Gaithersburg, MD · CIK 0001636613
Offering snapshot reported Mar 24, 2015 · SEC filing
- Reported sold
- $8M Offering amount: $16M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $10 Reported outside-investor minimum
- First sale
- Mar 10, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 24, 2015 | Initial | $8,000,000 | No comparison | 7 | SEC filing |
| Mar 24, 2015 | Initial | $42,000,000 | No comparison | 60 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-236532
Source: Form D, filed Mar 24, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Drutz | Director |
| William Enright | Director, Executive |
| Florent Gros | Director |
| Philip Hodges | Director |
| Philippe Pouletty | Director |
| Scot Roberts | Executive |
| Klaus Schafer | Director |
| Marten Steen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
19 Firstfield Road
Gaithersburg, MD, 20878
Gaithersburg, MD, 20878